Gossamer Bio, Inc. - GOSS

SEC Filings Our GOSS Tweets

About Gravity Analytica

Recent News

12.05.2025 - Mapping the Diagnostic Journey of Patients With Pulmonary Hypertension Associated With Interstitial Lung Disease
12.05.2025 - A Mixed Methods Analysis of Undertreatment and Delays in Therapy Escalation in Pulmonary Arterial Hypertension: Insights From a Real-world Patient Journey Study in the US
11.13.2025 - Seralutinib Preserved Lung Function and Displayed Broad Anti-Fibrotic Activity in Models of Pulmonary Fibrosis
11.13.2025 - Mapping the Diagnostic Journey of Patients With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD): A Retrospective U.S. Claims Analysis
09.30.2025 - Seralutinib reduces vessel wall volume and increases small pulmonary artery vessel volume: Insights from AI-driven CT imaging analysis
09.30.2025 - Seralutinib decreases endotrophin (PRO-C6) production, a mediator of fibrosis and inflammation, in an in vitro model of pulmonary fibrosis
09.28.2025 - Seralutinib shows significant anti-fibrotic effects: Evidence from patient-derived models
09.28.2025 - Seralutinib targets fibrotic pathways in IPF: Evidence from single-cell transcriptomics
09.28.2025 - Seralutinib demonstrates in vitro reduction of vascular inflammatory drivers underlying pulmonary hypertension
09.25.2025 - Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension

Recent Filings